Validant acquires Clinical Outcomes Solutions, a global leader in clinical outcomes assessment research services

Linda Howard General news

  • Adds complementary services in high growth sub-segment of HEOR
  • Expands geographic presence with offices across the US and UK
Image

Validant, a leading global quality, compliance and regulatory consulting group, has acquired Clinical Outcomes Solutions (“COS”), a global leader in clinical outcomes assessments (COA).

COS was founded in 2013 and has developed a leadership position in COA through its patient-centered approach and by building the deepest and broadest set of quantitative, scientific and analytical capabilities in the market. COA is a fast-growing niche of the health economics and outcomes research (HEOR) market, bringing the patient’s perspective to drug development. Headquartered in the UK, COS also has a significant presence in the US, with offices in Tucson (Arizona) and Chicago (Illinois) serving a broad range of biopharma clients worldwide.

Validant’s acquisition of COS is another important step in its international growth strategy, focused on combining best-in-class regulatory driven life science consultancies, and continuing their growth with further investment.

Today’s announcement follows Validant’s acquisition of Greenleaf Health, a leading U.S. Food and Drug Administration (FDA) regulatory consulting firm in April 2021; December 2020 acquisition of Oriel STAT A MATRIX, a New Jersey-based global consultancy and training firm; November 2020 acquisition of IDEC, a leading regulatory consultancy in Japan; and the acquisition of DataRevive in 2019, a regulatory strategy and consultancy for global clients, based in Washington D.C.

Commenting on the announcement, Patrick Ronan, CEO of Validant, said: “We are once again delighted to welcome another best-in-class provider into the Validant family, further expanding the Group’s service offering into HEOR and COA. Clinical Outcomes Solutions is a true category leader supporting customers across all facets of clinical outcomes research to improve patient care. We look forward to working together to better serve our combined customers.

Stacie Hudgens, CEO of COS said: “The team and I have spent the last eight years developing innovative scientific methods to capture and communicate the patient voice. In Validant, we have found a company that shares our patient-centered beliefs, and we look forward to working together to grow our business, helping clients and patients around the world.”

Achelous Partners provided investment banking and advisory services, and Taylor Wessing provided legal advice to the shareholders of COS.

OMM provided legal advice, RSM Global provided financial and accounting advice, Deloitte provided tax advice, and Howden provided insurance advice to Validant.